As expected, all ovarian cancers detected were in MSH2 carriers, consistent with ovarian cancer risk of 17%.3 Screening led to diagnosis in half of the studies (Online Supplemental Figure 3). This evidence concerns the gene MSH2 and ovarian carcinoma.